Screener
Zevra Therapeutics, Inc. ZVRA Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsAndOtherReceivablesNetCurrent.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s accounts receivable?
- Zevra Therapeutics, Inc. (ZVRA) reported accounts receivable of $22.49M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Zevra Therapeutics, Inc.'s accounts receivable increased by 23.1% year-over-year, from $18.27M to $22.49M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accounts receivable?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accounts receivable has grown at a 55.2% compound annual growth rate (CAGR), from $2.58M to $23.26M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about Zevra Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude